



Efficacy End-Point Subgroup

BNT162b2, 30 µg (N=21,669)

Placebo (N=21,686)

VE (95% CI)

No. of participants

Surveillance time

No. of participants

Surveillance time

percent

person-yr (no. at risk)

person-yr (no. at risk)

percent

Covid-19 occurrence

After dose 1	50	4.015 (21,314)	275	3.982 (21,258)	82.0 (75.6–86.9)
After dose 1 to before dose 2	39		82		52.4 (29.5–68.4)
Dose 2 to 7 days after dose 2	2		21		90.5 (61.0–98.9)
≥7 Days after dose 2	9		172		94.8 (89.8–97.6)